Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4[phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid
View Patent ↗Novel salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid characterized by their X-ray powder diffraction pattern and solid-state NMR spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and Alzheimer's Disease.
1. A Form A atorvastatin benzathine having an x-ray powder diffraction pattern containing the following 2θ peaks measured using CuK α radiation: 14.0 and 15.1.
2. A Form B atorvastatin benzathine having an x-ray powder diffraction pattern containing the following 2θ peaks measured using CuK α radiation: 8.3, 10.2, 14.4, 15.8, 18.6, 21.8, and 23.3.
3. A Form C atorvastatin benzathine having an x-ray powder diffraction pattern containing the following 2θ peaks measured using CuK α radiation: 3.9, 6.9, 7.9, 9.7, and 12.8.
4. A Form A atorvastatin benzathine having an x-ray powder diffraction pattern containing the following 2θ peaks measured using CuK α radiation: 9.1, 14.0, 15.1, 15.5, 16.1, 16.4, 18.2, 19.1, 19.6, 20.5, 21.3, 22.1, 22.5, 23.0, 25.2, 25.9, 26.1, 26.5, 28.0, and 28.6.
5. A Form B atorvastatin benzathine having an x-ray powder diffraction pattern containing the following 2θ peaks measured using CuK α radiation: 8.3, 9.1, 10.2, 11.7, 13.2, 14.4, 15.8, 16.6, 17.1, 18.6, 19.1, 19.4, 19.7, 20.6, 20.9, 21.4, 21.8, 22.3, 22.6, 23.3, 23.5, 24.3, 25.0, 26.5, 26.8, 27.4, 27.9, 28.2, 28.9, 29.1, and 29.7.
6. A Form C atorvastatin benzathine having an x-ray powder diffraction pattern containing the following 2θ peaks measured using CuK α radiation: 3.9, 6.9, 7.9, 9.7, 11.9, 12.8, 13.2, 15.5, 16.3, 16.8, 17.2, 18.9, 19.5, 19.9, 20.4, 20.7, 21.4, 23.0, 23.4, 24.0, 24.3, 24.6, 25.9, and 26.2.